https://www.biopharmawatch.com/news/ACB/aurora-cannabis-refutes-curaleaf-bid BiopharmaWatch en 2026-09-14T18:12:00.000Z Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts https://www.biopharmawatch.com/news/HCA/meditech-expanse-ehr-hca-healthcare-implementation BiopharmaWatch en 2026-09-14T17:30:00.000Z MEDITECH Expanse EHR Live Across First Full U.S. Divisions of HCA Healthcare https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-approval-ameluz-sbcc-treatment BiopharmaWatch en 2026-09-14T13:26:00.000Z Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma https://www.biopharmawatch.com/news/HSTM/healthstream-defines-enterprise-clinical-workforce-platform BiopharmaWatch en 2026-09-14T13:25:00.000Z HealthStream Defines a New Enterprise Category Alongside the EHR and ERP, the Enterprise Clinical Workforce Platform (ECWP) https://www.biopharmawatch.com/news/PACS/pacs-group-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-09-14T13:15:00.000Z PACS Group, Inc. to Present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15, 2026 https://www.biopharmawatch.com/news/NTHI/neonc-moves-neo100-regulatory-test BiopharmaWatch en 2026-09-14T13:07:00.000Z Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-14T13:05:00.000Z Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-robert-plenge-board-directors BiopharmaWatch en 2026-09-14T13:05:00.000Z BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors https://www.biopharmawatch.com/news/SNY/sanofi-cheplapharm-strategic-partnership-mature-medicines BiopharmaWatch en 2026-09-14T13:03:00.000Z Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines https://www.biopharmawatch.com/news/AZN/susan-g-komen-astrazeneca-patient-navigation BiopharmaWatch en 2026-09-14T13:00:00.000Z Susan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All https://www.biopharmawatch.com/news/CON/concentra-expands-florida-footprint-daytona-beach BiopharmaWatch en 2026-09-14T13:00:00.000Z Concentra Expands Florida Footprint with New Daytona Beach Medical Center https://www.biopharmawatch.com/news/AMGN/fda-approves-reduced-monitoring-time-imdelltra BiopharmaWatch en 2026-09-14T13:00:00.000Z FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® https://www.biopharmawatch.com/news/DARE/dare-bioscience-sildenafil-cream-phase-1-study BiopharmaWatch en 2026-09-14T12:50:00.000Z Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil https://www.biopharmawatch.com/news/HYFT/mindwalk-secures-30-million-credit-facility BiopharmaWatch en 2026-09-14T12:46:00.000Z MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion https://www.biopharmawatch.com/news/DWTX/dogwood-completes-enrollment-halneuron-phase-2b-trial BiopharmaWatch en 2026-09-14T12:45:00.000Z Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial https://www.biopharmawatch.com/news/AVXL/iss-recommends-anavex-director-nominees BiopharmaWatch en 2026-09-14T12:38:12.000Z Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-data-aacr-conference BiopharmaWatch en 2026-09-14T12:35:12.000Z Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-nerviano-license-agreement-amendment BiopharmaWatch en 2026-09-14T12:30:00.000Z Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement https://www.biopharmawatch.com/news/ONCO/onconetix-bridge-financing-realbotix-acquisition BiopharmaWatch en 2026-09-14T12:30:00.000Z Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-fda-rmat-designation-tn-401 BiopharmaWatch en 2026-09-14T12:30:00.000Z Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy https://www.biopharmawatch.com/news/VNRX/volitionrx-prepayment-senior-secured-note BiopharmaWatch en 2026-09-14T12:17:00.000Z VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 https://www.biopharmawatch.com/news/PBM/psyence-texas-ibogaine-research-corporation BiopharmaWatch en 2026-09-14T12:01:32.000Z Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development https://www.biopharmawatch.com/news/TELO/telomir-research-ohio-state-anti-cancer-activity BiopharmaWatch en 2026-09-14T12:00:00.000Z Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models https://www.biopharmawatch.com/news/QTRX/quanterix-names-dr-yuri-fesko-cmo BiopharmaWatch en 2026-09-14T12:00:00.000Z Quanterix Names Dr. Yuri Fesko Chief Medical Officer https://www.biopharmawatch.com/news/ADUS/addus-homecare-acquires-accentcare-personal-care-division BiopharmaWatch en 2026-09-14T12:00:00.000Z Addus HomeCare Announces a Definitive Agreement to Acquire Personal Care Division of AccentCare https://www.biopharmawatch.com/news/OABI/omniab-investor-analyst-day-october-2026 BiopharmaWatch en 2026-09-14T12:00:00.000Z OmniAb to Host Investor & Analyst Day on October 6, 2026 https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-janx013 BiopharmaWatch en 2026-09-14T12:00:00.000Z Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 https://www.biopharmawatch.com/news/WAT/waters-launches-bd-facsdiscover-a7-cell-analyzer BiopharmaWatch en 2026-09-14T12:00:00.000Z Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer https://www.biopharmawatch.com/news/EVAX/evaxion-ai-immunology-autoimmune-diseases BiopharmaWatch en 2026-09-14T12:00:00.000Z Evaxion applies its AI-Immunology™ platform in autoimmune diseases https://www.biopharmawatch.com/news/AKBA/akebia-first-patient-phase-2-ebribafusp-trial BiopharmaWatch en 2026-09-14T12:00:00.000Z Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases https://www.biopharmawatch.com/news/RADX/radiopharm-rad101-phase-2b-trial-data-sno26 BiopharmaWatch en 2026-09-14T12:00:00.000Z Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting https://www.biopharmawatch.com/news/NSRX/nasus-pharma-fda-clearance-ns002-anaphylaxis-study BiopharmaWatch en 2026-09-14T12:00:00.000Z Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis https://www.biopharmawatch.com/news/LPCN/lipocine-bloom-phase-3-study-lpcn-1154-postpartum-depression BiopharmaWatch en 2026-09-14T12:00:00.000Z Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression https://www.biopharmawatch.com/news/HIND/vyome-appoints-jerry-leonard-cfo BiopharmaWatch en 2026-09-14T12:00:00.000Z Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-fda-clearance-tbs-2025-aml BiopharmaWatch en 2026-09-14T11:45:00.000Z TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers https://www.biopharmawatch.com/news/CGC/canopy-growth-shareholder-vote-reminder-september-2023 BiopharmaWatch en 2026-09-14T11:30:00.000Z Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline https://www.biopharmawatch.com/news/OGN/organon-fda-review-miu-della-hormone-free-iud BiopharmaWatch en 2026-09-14T11:30:00.000Z Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device https://www.biopharmawatch.com/news/MDT/medtronic-launches-exchange-offer-minimed-separation BiopharmaWatch en 2026-09-14T11:30:00.000Z Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc. https://www.biopharmawatch.com/news/MMED/minimed-files-form-s4-registration-statement BiopharmaWatch en 2026-09-14T11:30:00.000Z MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement https://www.biopharmawatch.com/news/GLAS/glass-house-mama-sue-athlete-balm-launch-california BiopharmaWatch en 2026-09-14T11:30:00.000Z Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-program-2026 BiopharmaWatch en 2026-09-14T11:30:00.000Z Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program https://www.biopharmawatch.com/news/BBNX/beta-bionics-fda-clearance-mint-patch-pump BiopharmaWatch en 2026-09-14T11:30:00.000Z Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-breast-cancer-study-update BiopharmaWatch en 2026-09-14T11:30:00.000Z Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study https://www.biopharmawatch.com/news/PHIO/phio-fda-submission-phase-2b-carcinoma BiopharmaWatch en 2026-09-14T11:00:00.000Z Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma https://www.biopharmawatch.com/news/BBNX/senseonics-partnership-beta-bionics-eversense-ilet BiopharmaWatch en 2026-09-14T11:00:00.000Z Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-positive-topline-data-canyon-1-study-daily BiopharmaWatch en 2026-09-14T11:00:00.000Z Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-executives-to-board BiopharmaWatch en 2026-09-14T11:00:00.000Z INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board https://www.biopharmawatch.com/news/MDWD/mediwound-escharex-phase-iii-value-study-update BiopharmaWatch en 2026-09-14T11:00:00.000Z Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-baird-2026-healthcare-conference BiopharmaWatch en 2026-09-14T11:00:00.000Z Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/NRXP/geneuro-awarded-patent-gnk-301-als-treatment BiopharmaWatch en 2026-09-14T11:00:00.000Z GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) https://www.biopharmawatch.com/news/IMCR/immunocore-tebe-am-trial-enrollment-kimmtrak BiopharmaWatch en 2026-09-14T11:00:00.000Z Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-presentation-pas-004-clinical-data BiopharmaWatch en 2026-09-14T11:00:00.000Z Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-14T11:00:00.000Z Seaport Therapeutics to Participate in September Investor Conferences https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-positive-results-phase-3-study BiopharmaWatch en 2026-09-14T11:00:00.000Z Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-fda-breakthrough-therapy-ap-sa02 BiopharmaWatch en 2026-09-14T11:00:00.000Z Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-virtual-event-rezilient3-data BiopharmaWatch en 2026-09-14T11:00:00.000Z Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-new-executives BiopharmaWatch en 2026-09-14T10:59:00.000Z Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer https://www.biopharmawatch.com/news/TYRA/tyra-announces-400-million-offering-common-stock BiopharmaWatch en 2026-09-14T10:45:00.000Z Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/TLX/fda-approves-telix-pixclara-brain-cancer-imaging-drug BiopharmaWatch en 2026-09-14T10:30:00.000Z FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara https://www.biopharmawatch.com/news/JNJ/amivantamab-chemotherapy-nsclc-survival BiopharmaWatch en 2026-09-14T08:10:00.000Z Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer https://www.biopharmawatch.com/news/BNTX/gotistobart-phase-3-study-results-lung-cancer BiopharmaWatch en 2026-09-14T08:00:00.000Z Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge https://www.biopharmawatch.com/news/BNTX/gotistobart-doubles-survival-squamous-nsclc BiopharmaWatch en 2026-09-14T08:00:00.000Z BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients https://www.biopharmawatch.com/news/NVO/novo-nordisk-rebrand-lasting-health-starts-now BiopharmaWatch en 2026-09-14T07:05:00.000Z Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture https://www.biopharmawatch.com/news/TAK/fda-accepts-ndas-zasocitinib-plaque-psoriasis BiopharmaWatch en 2026-09-14T07:00:00.000Z U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations https://www.biopharmawatch.com/news/CLLS/cellectis-strategic-transformation-in-vivo-gene-editing BiopharmaWatch en 2026-09-14T06:40:00.000Z Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company https://www.biopharmawatch.com/news/NBTX/nanobiotix-phase-1-results-nbtxr3-nsclc BiopharmaWatch en 2026-09-14T06:00:00.000Z NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-ptk7-adc-target-nsclc-wclc-2026 BiopharmaWatch en 2026-09-14T01:30:00.000Z Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 https://www.biopharmawatch.com/news/CGEM/zipalertinib-chemotherapy-nsclc-trial-results BiopharmaWatch en 2026-09-13T23:15:00.000Z Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-panorama-study-results BiopharmaWatch en 2026-09-13T21:00:00.000Z Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-monotherapy-significant-benefit-pembrolizumab BiopharmaWatch en 2026-09-13T11:00:00.000Z Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China https://www.biopharmawatch.com/news/JNJ/rybrevant-amivantamab-lung-cancer-study-results BiopharmaWatch en 2026-09-13T00:00:00.000Z Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating...